论文部分内容阅读
[目的]探讨CD44V5表达与食管癌患者预后的关系。[方法]应用免疫组织化学S-P法对50例随访资料完整的食管癌标本进行CD44V5测定,并分析其与患者预后的关系。[结果]50例患者中,CD44V5阳性39例,其3年生存率为15.4%;CD44V5阴性11例,其3年生存率为45.5%(P<0.05)。单因素及多因素分析均显示CD44V5阳性表达为食管癌患者预后的独立危险因素。[结论]CD44V5的高表达预示着食管癌患者预后不良,是食管癌患者预后的独立危险因素。
[Objective] To investigate the relationship between the expression of CD44V5 and the prognosis of patients with esophageal cancer. [Method] The immunohistochemical S-P method was used to determine the CD44V5 in 50 cases of esophageal cancer with complete follow-up data and to analyze its relationship with the prognosis. [Results] Of the 50 patients, 39 patients were positive for CD44V5 with a 3-year survival rate of 15.4% and 11 patients were negative for CD44V5. The 3-year survival rate was 45.5% (P <0.05). Univariate and multivariate analysis showed that the positive expression of CD44V5 was an independent risk factor for the prognosis of patients with esophageal cancer. [Conclusion] The high expression of CD44V5 predicts the poor prognosis of esophageal cancer patients, which is an independent risk factor for the prognosis of esophageal cancer patients.